Monday, August 31, 2015

Novartis' Nebraska problems continue, forcing GlaxoSmithKline recall

The troubled Nebraska manufacturing plant owned by Novartis has translated into a problem for another drug maker as the Lincoln Journal Star reported that GlaxoSmithKline is recalling nearly 400,000 bottles of the blood pressure drug DynaCirc CR.

Novartis' Nebraska problems continue, forcing GlaxoSmithKline recall

0 comments

The troubled Nebraska manufacturing plant owned by Novartis has translated into a problem for another drug maker as the Lincoln Journal Star reported that GlaxoSmithKline is recalling nearly 400,000 bottles of the blood pressure drug DynaCirc CR.

Novartis produces its own drugs, prescription and over-the-counter, but also manufactures drugs on a contract basis for other manufacturers at the plant near Lincoln. In January, Novartis recalled several of its over-the-counter medicines including Excedrin, Bufferin, GasX and NoDoz.

Endo Pharmaceuticals of Chadds Ford also had to shift production of some of its drugs to an Alabama facility because of the Novartis problems.

The GSK blood pressure medicine in question is the 5 and 10 milligram pills that come in 30-count bottles, according to the recall notice on the U.S. Food and Drug Administration web site.

The reason given mentions "procedural controls related to line clearance during the packaging process at the Novartis Consumer Health site."

The link to the Journal Star story is here.

The link to the FDA page is here, but it's a long list, so scrolling is required.

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com or 215-854-4506.

David Sell
Also on Philly.com:
letter icon Newsletter